Five Below FIVE 深 沪
已收盘 12-19 16:00:00 美东时间
182.07
+0.030
+0.02%
华盛通- 最 高183.5343
- 今 开183.01
- 成交量 179.35万股
- 最 低 180.80
- 昨 收 182.04
- 总市值 100.24亿
- 52周最高 184.5725
- 市盈率 静 39.60
- 换手率 3.26%
- 52周最低 52.38
- 委 比 -33.33%
- 总股本 5505.80万
- 历史最高 237.86
- 量 比 1.49
- 振 幅 1.50%
- 历史最低 25.00
- 每 手 1
- 风险率 32.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wells Fargo Maintains Overweight on Five Below, Raises Price Target to $200
Wells Fargo analyst Edward Kelly maintains Five Below (NASDAQ:FIVE) with a Overweight and raises the price target from $190 to $200.
12-19 21:51
Price Over Earnings Overview: Five Below
In the current market session, Five Below Inc. (NASDAQ:FIVE) stock price is at ...
12-15 23:01
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
Truist thinks the post-earnings rally for Five Below can extend
Truist Securities thinks the rally can extend for Five Below (FIVE) after the retailer's strong Q3 earnings report. Amid the tough tariff backdrop, Five Below (FIVE) is seen as having the right needs-...
12-09 04:52
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
12-05 08:35
Looking Into Five Below Inc's Recent Short Interest
Five Below Inc's (NYSE:FIVE) short interest as a percent of float has fallen 14...
12-05 04:00
Top retail stocks by YTD performance as Costco flops
In the face of consumer spending concerns, government shutdowns, and reduced SNAP payments, certain retail stocks have demonstrated remarkable resilience. We present the best performing retail stocks ...
12-05 02:28
美股开盘：美股周四小幅高开 市场降息预期升温
道指涨0.11%，标普500指数涨0.21%，纳指涨0.31%；Meta涨超5%，CEO扎克伯格计划对元宇宙项目预算削减至多30%；小鹏汽车涨近4%，英伟达涨逾1%>>
12-04 22:33
Mizuho Maintains Neutral on Five Below, Raises Price Target to $165
Mizuho analyst David Bellinger maintains Five Below (NASDAQ:FIVE) with a Neutral and raises the price target from $160 to $165.
12-04 21:28
Five Below Sees Q4 Adj EPS $3.36-$3.54 vs $3.10 Est; Sees Sales $1.580B-$1.610B vs $1.555B Est
Five Below (NASDAQ:FIVE) is looking for Q4 Adj EPS of $3.36-$3.54 vs $3.10 analyst estimate. sees sales of $1.580 billion-$1.610 billion vs $1.555 billion analyst estimate.
12-04 05:02
